Pipeline
The Best Target & The Best Chemical
Overview
Pharos iBio aims for global technology out-licensing by developing new drugs focusing on treatments for rare and refractory diseases through Chemiverse, an AI-based new drug development platform.
-
PHI-101-OC
(Ovarian Cancer)Global Market Size KRW 5.3T -
PHI-101-TNBC
(Triple Negative
Breast Cancer)Global Market Size KRW 2.2T -
PHI-101-AML
(Acute Myelogenous
Leukemia)Global Market Size KRW 570.4B -
PHI-101-RS
(Radiation
Sensitizer)Global Market Size KRW 1.2T
-
PHI-201
(K-RAS protein
inhibitor)Global Market Size KRW 400B -
PHI-401
(ALK resistance
protein inhibitor)Global Market Size KRW 2.9T -
PHI-301
(FAK Hub protein
inhibitor)Global Market Size KRW 1.5T -
PHI-501
(pan-RAF/DDRs
inhibitor)Global Market Size KRW 4.5T
Pipeline Development Progress
구분 | Pipeline | Lead & Tox | Pre-Clinical | IND | Phase 1 | Phase 2 |
---|---|---|---|---|---|---|
PHI-101 | AML (Acute Myelogenous Leukemia) |
|
||||
OC (Ovarian Cancer) |
|
|||||
TNBC (Triple Negative Breast Cancer) |
|
|||||
Radiation Sensitizer |
|
|||||
PHI-201 | K-Ras Hub-protein inhibitor |
|
||||
PHI-301 | FAK Hub-protein inhibitor |
|
||||
PHI-401 | FGFR |
|
||||
PHI-501 | pan-RAF/DDRs inhibitor |
|